WHITE PAPER : A GAME-CHANGING PRECLINICAL TESTING MODEL FOR SYNERGISTIC IMMUNO-ONCOLOGY DRUG CANDIDATES

This white paper reviews the current benefits of immuno-oncology therapeutic strategies over conventional treatments and highlights the main difficulty facing drug developers today: the high combinatorial complexity of finding effective new therapies.

FAST AND COST-EFFECTIVE SOLUTIONS FOR IN VIVO ANTICANCER DRUG EVALUATION, USING THE CHICKEN EMBRYO MODEL

Inovotion has developed a new ground-breaking way to test in vivo efficacy and toxicity of anticancer drug candidates, based on human cancer cell xenografts on chicken embryos. This fast, sensitive, reliable, and affordable assay is applicable to all preclinical anticancer drug discovery programs, from small molecules to immuno-therapies and combinations. 

During this webinar Xavier Rousset will discuss : 

• Benefits of early in vivo efficacy evaluation to optimize the probability of success for drug candidates
• Chicken embryo model and its characteristics
• Benefits of the chicken embryo model for filling the gaps between in vitro studies and mouse models
• Comparative analysis of the chicken embryo model vs the mouse model
• Drug efficacy analysis on tumor growth, metastatic invasion, angiogenesis, immuno-oncology, biomarkers and mechanisms of action in the chicken embryo model
• Case Studies

INOVOTION EXPANDS IT'S R&D TEAM ! 

Inovotion welcomes three new members to it's R&D team!

They bring significant new competencies to the company, and will boost our research projects.

Inovotion is committed to recruiting new talents and supporting them in their evolution.

We are thrilled to welcome them in our team!

Feel free to contact us if you to are interested in joining Inovotion team or if you wish to discuss your future projects with us ! 

DAUDI-RITUXIMAB ASSAY

INOVOTION has a new in vivo assay for Anti-CD20 therapies and B-Cell targeting.

Our R&D team has recently set up and validated a highly specific new assay based on Rituximab and Daudi cells on chicken embryos.

This changes the landscape by opening a large range of possibilities for rapidly evaluating anti-CD20 therapies and combinations.

Let’s talk about your projects to see how this new assay will further your R&D !!

Feel free to contact us if you wish to talk about your projects to see how this new assay will further your R&D !!

AN UNIQUE IN-VIVO MODEL FOR FAST ADC EFFICACITY RANKING: THE CHICKEN EMBRYO'S CAM BASED ASSAY

Learn more about our next-generation solution for your ranking needs.

The video provides an in-depth description of INOVOTION’s unique model, as applied to fast ADC efficacy ranking.

Find out more about this world class solution to your preclinical ranking need !

UPCOMING EVENTS WHERE YOU CAN MEET US:

- NLS Days – Digital Nordic Life Science Days 

20-23 April

- Meet2Win

6-7 May

- PEGS Boston 

11-13 May

- BIO Digital 

10-11 & 14-18 June

ABOUT US 

Optimizing your preclinical and Drug Discovery studies is of prime importance, and INOVOTION has developed a solution based on its unique and cutting-edge in vivo technology.

As a Contract Research Organization (CRO) dedicated to in vivo evaluation for Drug Discovery mainly in oncology and immuno-oncology, INOVOTION is a sought-after partner for Pharma and Biotech companies as well as academic labs all over the world.

Our main missions are to:

• Help you find the best candidate anti-cancer treatment
• Detect the first in vivo toxicity effects of your candidate compounds
• Improve productivity and Return-On-Investment of your preclinical and Drug Discovery process by maximizing your lead optimization phase 
• Accelerate the overall Drug Discovery process to answer unmet medical needs in oncology.

Any questions about Inovotion's technology? 

Contact us at : contact@inovotion.com

INOVOTION SAS
HQ & Lab Facilities

+33 475 549 512

5 ave du Grand Sablon
38700 La Tronche
France

INOVOTION Inc

185 Alewife Brook Parkway, Suite 210
Cambridge, MA 02138

USA

This email was sent to [[EMAIL_TO]] for marketing purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused. To prevent further emails, click here: Manage your preferences